Difference between revisions of "CNS5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(5 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
If empty (no name is present), please volunteer to create content for that disease! | If empty (no name is present), please volunteer to create content for that disease! | ||
− | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | + | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> |
− | |||
− | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | |+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | ||
Line 19: | Line 17: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | | | + | |CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]] | ||
|Disease | |Disease | ||
|Meenakshi Mehrotra | |Meenakshi Mehrotra | ||
Line 30: | Line 48: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Oligodendroglioma, IDH- | + | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] |
+ | |Disease | ||
+ | |Riley Lochner (trainee), Shashi Shetty (mentor) | ||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
Line 39: | Line 59: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Glioblastoma, IDH- | + | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] |
+ | |Disease | ||
+ | |Meenakshi Mehrotra | ||
| | | | ||
| | | | ||
Line 46: | Line 68: | ||
|LS | |LS | ||
| | | | ||
− | |Moved from " | + | |Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added |
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] |
+ | |Disease | ||
+ | |Scott Smith | ||
|6/27/2023 | |6/27/2023 | ||
| | | | ||
Line 57: | Line 81: | ||
|2021 template added (page created 6/27/23) | |2021 template added (page created 6/27/23) | ||
|- | |- | ||
− | |Angiocentric | + | |[[CNS5:Angiocentric_glioma|Angiocentric glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 66: | Line 92: | ||
| | | | ||
|- | |- | ||
− | |Polymorphous | + | |[[CNS5:Polymorphous_low-grade_neuroepithelial_tumour_of_the_young|Polymorphous low-grade neuroepithelial tumour of the young]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 75: | Line 103: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 84: | Line 114: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] |
+ | |Disease | ||
+ | |Laveniya Satgunaseelan (Linda Cooley - previous version) | ||
| | | | ||
| | | | ||
Line 93: | Line 125: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_hemispheric_glioma,_H3_G34-mutant|Diffuse hemispheric glioma, H3 G34-mutant]] |
+ | |Disease | ||
+ | |Xiaolin (Lynn) Hu | ||
|2/21/2022 | |2/21/2022 | ||
| | | | ||
Line 102: | Line 136: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] |
+ | |Disease | ||
+ | |Madina Sukhanova | ||
|10/28/2022 | |10/28/2022 | ||
| | | | ||
Line 111: | Line 147: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Infant- | + | |[[CNS5:Infant-type_hemispheric_glioma|Infant-type hemispheric glioma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
| | | | ||
| | | | ||
Line 118: | Line 157: | ||
| | | | ||
| | | | ||
− | |||
|- | |- | ||
− | |Pilocytic | + | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] |
+ | |Disease | ||
+ | |Jeremy Pulvers | ||
|9/13/2022<br /> | |9/13/2022<br /> | ||
| | | | ||
Line 129: | Line 169: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |High- | + | |[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 138: | Line 180: | ||
| | | | ||
|- | |- | ||
− | |Pleomorphic | + | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 147: | Line 191: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Subependymal | + | |[[CNS5:Subependymal_giant_cell_astrocytoma|Subependymal giant cell astrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 156: | Line 202: | ||
| | | | ||
|- | |- | ||
− | |Chordoid | + | |[[CNS5:Chordoid_glioma|Chordoid glioma]] |
− | | | + | |Disease |
+ | | | ||
+ | | | ||
| | | | ||
| | | | ||
Line 165: | Line 213: | ||
| | | | ||
|- | |- | ||
− | |Astroblastoma, MN1- | + | |[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 174: | Line 224: | ||
| | | | ||
|- | |- | ||
− | |Ganglioglioma||Disease | + | |[[CNS5:Ganglioglioma|Ganglioglioma]] |
+ | |Disease | ||
+ | |Leila Moayed-Aloei | ||
|6/30/2022 | |6/30/2022 | ||
| | | | ||
Line 183: | Line 235: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Gangliocytoma||Disease | + | |[[CNS5:Gangliocytoma|Gangliocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 192: | Line 246: | ||
| | | | ||
|- | |- | ||
− | |Desmoplastic | + | |[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 201: | Line 257: | ||
| | | | ||
|- | |- | ||
− | |Dysembryoplastic | + | |[[CNS5:Dysembryoplastic_neuroepithelial_tumour|Dysembryoplastic neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 210: | Line 268: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_glioneuronal_tumour_with_oligodendroglioma-like_features_and_nuclear_clusters|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 219: | Line 279: | ||
| | | | ||
|- | |- | ||
− | |Papillary | + | |[[CNS5:Papillary_glioneuronal_tumour|Papillary glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 228: | Line 290: | ||
| | | | ||
|- | |- | ||
− | |Rosette- | + | |[[CNS5:Rosette-forming_glioneuronal_tumour|Rosette-forming glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 237: | Line 301: | ||
| | | | ||
|- | |- | ||
− | |Myxoid | + | |[[CNS5:Myxoid_glioneuronal_tumour|Myxoid glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 246: | Line 312: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 255: | Line 323: | ||
| | | | ||
|- | |- | ||
− | |Multinodular and | + | |[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 264: | Line 334: | ||
| | | | ||
|- | |- | ||
− | |Dysplastic | + | |[[CNS5:Dysplastic_cerebellar_gangliocytoma_(Lhermitte-Duclos_disease)|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 273: | Line 345: | ||
| | | | ||
|- | |- | ||
− | |Central | + | |[[CNS5:Central_neurocytoma|Central neurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 282: | Line 356: | ||
| | | | ||
|- | |- | ||
− | |Extraventricular | + | |[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 291: | Line 367: | ||
| | | | ||
|- | |- | ||
− | |Cerebellar | + | |[[CNS5:Cerebellar_liponeurocytoma|Cerebellar liponeurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 300: | Line 378: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 309: | Line 389: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 318: | Line 400: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] |
− | | | + | |Disease |
+ | | | ||
+ | | | ||
| | | | ||
| | | | ||
Line 327: | Line 411: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_ependymoma|Posterior fossa ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 336: | Line 422: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_A_(PFA)_ependymoma|Posterior fossa group A (PFA) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 345: | Line 433: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_B_(PFB)_ependymoma|Posterior fossa group B (PFB) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 354: | Line 444: | ||
| | | | ||
|- | |- | ||
− | |Spinal | + | |[[CNS5:Spinal_ependymoma|Spinal ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 363: | Line 455: | ||
| | | | ||
|- | |- | ||
− | |Spinal | + | |[[CNS5:Spinal_ependymoma,_MYCN-amplified|Spinal ependymoma, MYCN-amplified]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 372: | Line 466: | ||
| | | | ||
|- | |- | ||
− | |Myxopapillary | + | |[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 381: | Line 477: | ||
| | | | ||
|- | |- | ||
− | |Subependymoma||Disease | + | |[[CNS5:Subependymoma|Subependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 390: | Line 488: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 3 (CHOROID PLEXUS TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 417: | Line 519: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_choroid_plexus_papilloma|Atypical choroid plexus papilloma]] |
− | + | |Disease | |
− | |||
− | |||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 435: | Line 530: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Choroid_plexus_carcinoma|Choroid plexus carcinoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 444: | Line 541: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 4 (EMBRYONAL TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] | ||
+ | |Disease | ||
+ | |Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | ||
+ | |9/20/21 | ||
| | | | ||
+ | |COMPLETE | ||
| | | | ||
+ | |Holli Drendel (interim)/Laveniya Satgunaseelan (LS) | ||
+ | |9/22/2022 | ||
+ | |2021 template added | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-wildtype|Medulloblastoma, SHH-activated and TP53-wildtype]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 471: | Line 583: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 480: | Line 594: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 489: | Line 605: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Medulloblastoma,_histologically_defined|Medulloblastoma, histologically defined]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 498: | Line 616: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_teratoid/rhabdoid_tumour|Atypical teratoid/rhabdoid tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 507: | Line 627: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cribriform_neuroepithelial_tumour|Cribriform neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 516: | Line 638: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Embryonal_tumour_with_multilayered_rosettes|Embryonal tumour with multilayered rosettes]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 525: | Line 649: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CNS_neuroblastoma,_FOXR2-activated|CNS neuroblastoma, FOXR2-activated]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 534: | Line 660: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] |
− | | | + | |Disease |
+ | | | ||
+ | | | ||
| | | | ||
| | | | ||
Line 543: | Line 671: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CNS_embryonal_tumour_NEC/NOS|CNS embryonal tumour NEC/NOS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 552: | Line 682: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 5 (PINEAL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineocytoma|Pineocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 570: | Line 713: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 579: | Line 724: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineoblastoma|Pineoblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 588: | Line 735: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 597: | Line 746: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 606: | Line 757: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Schwannoma|Schwannoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 624: | Line 788: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Neurofibroma|Neurofibroma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 633: | Line 799: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Perineurioma|Perineurioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 642: | Line 810: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 651: | Line 821: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 660: | Line 832: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 669: | Line 843: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 678: | Line 854: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 7 (MENINGIOMA) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Meningioma|Meningioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 696: | Line 885: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 714: | Line 916: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangiomas_and_vascular_malformations|Haemangiomas and vascular malformations]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 723: | Line 927: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangioblastoma|Haemangioblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 732: | Line 938: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rhabdomyosarcoma|Rhabdomyosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 741: | Line 949: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Intracranial_mesenchymal_tumour,_FET::CREB_fusion-positive|Intracranial mesenchymal tumour, FET::CREB fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 750: | Line 960: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 759: | Line 971: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 768: | Line 982: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Ewing_sarcoma|Ewing sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 777: | Line 993: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 786: | Line 1,004: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chondrosarcoma|Chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 795: | Line 1,015: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chordoma|Chordoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 804: | Line 1,026: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 9 (MELANOCYTIC TUMOURS) |
− | |||
| | | | ||
− | + | ---- | |
− | |||
− | |||
| | | | ||
− | + | ---- | |
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 831: | Line 1,057: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 840: | Line 1,068: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 858: | Line 1,099: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 867: | Line 1,110: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 876: | Line 1,121: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 885: | Line 1,132: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 894: | Line 1,143: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 903: | Line 1,154: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
+ | |7/2/2023 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |MS | ||
| | | | ||
+ | |2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"? | ||
+ | |- | ||
+ | |[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 918: | Line 1,175: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 928: | Line 1,186: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 939: | Line 1,198: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]] |
+ | |Disease | ||
| | | | ||
| | | | ||
Line 946: | Line 1,206: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 956: | Line 1,216: | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |CHAPTER 11 (GERM CELL TUMOURS) | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 993: | Line 1,262: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 12 (TUMOURS OF THE SELLAR REGION |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
| | | | ||
− | + | ---- | |
| | | | ||
− | + | ---- | |
− | |||
− | |||
|- | |- | ||
− | | | + | |[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]] |
− | + | |Disease | |
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,026: | Line 1,292: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,036: | Line 1,303: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,047: | Line 1,315: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]] |
− | + | |Disease | |
| | | | ||
− | |||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,063: | Line 1,325: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Pituitary_blastoma|Pituitary blastoma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,074: | Line 1,337: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 13 (METASTASES TO THE CNS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,091: | Line 1,364: | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS) | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] |
Latest revision as of 14:00, 25 February 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.